These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8656254)

  • 41. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toxicity profile and objective response of paclitaxel in metastatic breast cancer.
    Ansari TN; Mahmood A; Khattak BK; Rasul S; Syed AS
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):200-3. PubMed ID: 15857589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.
    Gelmon KA; O'Reilly SE; Tolcher AW; Campbell C; Bryce C; Ragaz J; Coppin C; Plenderleith IH; Ayers D; McDermott B; Nakashima L; Healey D; Onetto N
    J Clin Oncol; 1996 Apr; 14(4):1185-91. PubMed ID: 8648373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
    Ibrahim NK; Samuels B; Page R; Doval D; Patel KM; Rao SC; Nair MK; Bhar P; Desai N; Hortobagyi GN
    J Clin Oncol; 2005 Sep; 23(25):6019-26. PubMed ID: 16135470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
    Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
    Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
    Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
    Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel activity in anthracycline refractory breast cancer patients.
    Vici P; Di Lauro L; Conti F; Capomolla E; Gionfra T; Amodio A; Lopez M
    Tumori; 1997; 83(3):661-4. PubMed ID: 9267484
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
    Hainsworth JD; Raefsky EL; Greco FA
    Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy.
    Michael M; Bishop JF; Levi JA; Bell DR; Zalcberg JR; Friedlander ML; Olver IN; Smith JG; Toner GC
    Med J Aust; 1997 May; 166(10):520-3. PubMed ID: 9196484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
    Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
    Villanueva C; Chaigneau L; Dufresne A; Thierry Vuillemin A; Stein U; Demarchi M; Bazan F; N'guyen T; Pivot X
    Breast; 2011 Aug; 20(4):329-33. PubMed ID: 21439823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.
    Donadio M; Manzin E; Berruti A; Bottini A; Gorzegno G; Danese S; DeFabiani E; Sarobba MG; Lorusso V; Castiglione F; Moro G; Bertetto O; Bumma C; Dogliotti L
    Cancer Chemother Pharmacol; 2001 May; 47(5):391-6. PubMed ID: 11391853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.